Diabetes prevention program outcomes study ppt

Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials. Layout table for investigator information Study Chair: David M. More Information. Additional Information: Study website. Clinical trials. Epub Oct Erratum in: Lancet. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over year follow-up: the Diabetes Prevention Program Outcomes Study.

Lancet Diabetes Endocrinol. Epub Sep Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. Predictive utilities of lipid traits, lipoprotein subfractions and other risk factors for incident diabetes: a machine learning approach in the Diabetes Prevention Program. Diabetes Care. Epub Nov J Clin Endocrinol Metab. Epub Jul Ann Intern Med. Epub Apr Erratum in: Ann Intern Med. Epub Oct 1. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program.

Diabet Med. The primary outcome of the second phase was the prevalence of a composite microvascular outcome. Secondary outcome measures included the development of cardiovascular disease. All active DPP study participants were eligible for continued follow-up, including those with and without diabetes.

The study found that prevention or delay of type 2 diabetes with lifestyle intervention or metformin in a high-risk population, as seen in the DPP study, can persist for at least 10 years. These documents are provided for reference purposes only. They were current when the study was conducted but may now be outdated. Main Menu. Press release. June 16, Chicago, Illinois.

Despite the benefits seen with diabetes prevention overall, there was no significant benefit seen with the individual interventions—metformin or the lifestyle intervention—with regard to heart disease or the development of kidney disease or diabetic retinopathy.

However, there were favorable trends with metformin in stroke reduction and for cardiovascular events in the subgroup of people who started the study before age The most recent results also showed the intensive lifestyle intervention group had a long-term reduction in the development of frailty.

The only long-term negative effect observed with any of the interventions was a modest increase in kidney disease with metformin, which appeared only in the oldest group of participants.

Research presentation details: Dr. CT For more information or to schedule an interview with Dr. Press contacts Daisy Diaz.